# AffyXell Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/affyxell-therapeutics

- Industry: Biotechnology
- Headquarters: Gimhae, South Korea
- Website: www.affyxell.com
- Total disclosed funding: $7.3M
- Latest round: Series A (Feb 1, 2021)
- Investors on record: 7

## About

AffyXell Therapeutics develops innovative cell and gene therapies utilizing mesenchymal stem cells and the Affimer® platform to address immune system-related diseases, aiming to restore immune balance for better patient outcomes.AffyXell Therapeutics is a biotechnology company founded in 2020 in Gimhae, South Korea. The company focuses on developing next-generation therapies for immune regulation. Founded by Seng-Ho Jeon, who has a history of working in the biotech sector, AffyXell has successfully raised USD 7.3 mn in its Series A funding round on February 1, 2021, with investments from notable firms such as Samsung Venture Investment and Shinhan Venture Investment. The total amount raised by the company to date is USD 7.3 mn, which corresponds to their latest funding round.AffyXell Therapeutics specializes in developing next-generation cell and gene therapies, primarily leveraging advanced technologies in mesenchymal stem cells (MSCs) and the Affimer® platform. Their core offerings focus on innovative therapeutics designed to restore immune balance and address diseases arising from immune system imbalances, such as autoimmune disorders and transplant rejection. By integrating DW-MSC platform capabilities for large-scale manufacturing with the Affimer® technology, AffyXell aims to create optimized therapies categorized under the AFX platform, specifically designed to enhance immunomodulatory functions. The end users of these products include healthcare providers and institutions focused on treating chronic and difficult-to-manage conditions, with an emphasis on the global market spanning Europe, North America, and Asia.AffyXell Therapeutics conducts its business through strategic partnerships and collaborations within the biopharmaceutical sector, primarily targeting healthcare institutions and research organizations. The company’s revenue is generated through development agreements and potential licensing deals related to its flagship AFX platform, which includes innovative therapies for immune regulation. The transactional structure often involves milestone payments linked to developmental progress, as well as royalties based on future sales of their therapeutic products. These arrangements facilitate both B2B interactions with large healthcare entities and partnerships with research institutions, ensuring comprehensive engagement within the biotherapeutics market.AffyXell Therapeutics plans to utilize the recently raised USD 7.3 mn from its Series A funding to further develop MSCs engineered to produce Affimer molecules that suppress the immune response and restore immune balance. The company aims to introduce new products focused on immune regulation and expand its reach into European and North American markets by 2023. These strategic initiatives will support their mission of delivering advanced therapies to healthcare providers and institutions, enhancing patient care in complex immune-related conditions.

## Funding rounds

- Series A, Feb 1, 2021, $7.3M — Shinhan Venture Investment, Samsung Venture Investment, Shinhan Securities, Smilegate Investment, Kolon Investment, Stonebridge Ventures, Gyeongnam Venture Investment

## Investors

- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series A
- Samsung Venture Investment (https://capitalatlas.ai/funds/samsung-venture-investment) — Series A
- Shinhan Securities (https://capitalatlas.ai/funds/shinhan-securities) — Series A
- Smilegate Investment (https://capitalatlas.ai/funds/smilegate-investment) — Series A
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A
- Stonebridge Ventures — Series A
- Gyeongnam Venture Investment (https://capitalatlas.ai/funds/gyeongnam-venture-investment) — Series A